Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Protara Therapeutics Inc TARA

Healthcare Biotechnology
Protara Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in advancing transformative therapies for people with cancer and rare diseases. The Company’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is... see more

Recent & Breaking News (NDAQ:TARA)

Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing

GlobeNewswire April 5, 2024

Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition

GlobeNewswire April 5, 2024

Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC

GlobeNewswire April 5, 2024

Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire March 13, 2024

Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

GlobeNewswire February 28, 2024

Protara Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire January 31, 2024

Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology

GlobeNewswire November 30, 2023

Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update

GlobeNewswire November 3, 2023

Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

GlobeNewswire October 23, 2023

Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ

GlobeNewswire September 20, 2023

Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire September 5, 2023

Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update

GlobeNewswire August 3, 2023

Protara Therapeutics Announces Dosing of First Patients in Phase 1b ADVANCED-1EXP Trial of TARA-002 in NMIBC Patients with Carcinoma in Situ

GlobeNewswire May 15, 2023

Protara Therapeutics Announces First Quarter 2023 Financial Results and Business Update

GlobeNewswire May 4, 2023

Protara Therapeutics Receives Regulatory Clearance from FDA to Commence Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

GlobeNewswire May 2, 2023

Protara Therapeutics Announces Positive Preliminary Data from ADVANCED-1 Phase 1a Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Phase 2 Clinical Development

GlobeNewswire April 28, 2023

Protara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

GlobeNewswire March 8, 2023

Protara Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire March 1, 2023

Protara Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day

GlobeNewswire February 2, 2023

Protara Therapeutics Announces Appointment of Patrick Fabbio as Chief Financial Officer

GlobeNewswire January 30, 2023